全文获取类型
收费全文 | 94127篇 |
免费 | 9064篇 |
国内免费 | 4684篇 |
专业分类
耳鼻咽喉 | 1073篇 |
儿科学 | 1117篇 |
妇产科学 | 1665篇 |
基础医学 | 12345篇 |
口腔科学 | 2122篇 |
临床医学 | 9754篇 |
内科学 | 15714篇 |
皮肤病学 | 1451篇 |
神经病学 | 5514篇 |
特种医学 | 3267篇 |
外国民族医学 | 21篇 |
外科学 | 11470篇 |
综合类 | 12592篇 |
现状与发展 | 19篇 |
一般理论 | 10篇 |
预防医学 | 6710篇 |
眼科学 | 2322篇 |
药学 | 9437篇 |
49篇 | |
中国医学 | 3513篇 |
肿瘤学 | 7710篇 |
出版年
2024年 | 133篇 |
2023年 | 718篇 |
2022年 | 1795篇 |
2021年 | 2537篇 |
2020年 | 1886篇 |
2019年 | 1980篇 |
2018年 | 2521篇 |
2017年 | 2328篇 |
2016年 | 2135篇 |
2015年 | 2890篇 |
2014年 | 3663篇 |
2013年 | 4025篇 |
2012年 | 5424篇 |
2011年 | 5502篇 |
2010年 | 3793篇 |
2009年 | 3389篇 |
2008年 | 4232篇 |
2007年 | 4371篇 |
2006年 | 4053篇 |
2005年 | 3559篇 |
2004年 | 3176篇 |
2003年 | 3385篇 |
2002年 | 3009篇 |
2001年 | 5990篇 |
2000年 | 5475篇 |
1999年 | 4652篇 |
1998年 | 1809篇 |
1997年 | 1428篇 |
1996年 | 881篇 |
1995年 | 768篇 |
1994年 | 694篇 |
1993年 | 569篇 |
1992年 | 2088篇 |
1991年 | 1818篇 |
1990年 | 1638篇 |
1989年 | 1581篇 |
1988年 | 1361篇 |
1987年 | 1243篇 |
1986年 | 1110篇 |
1985年 | 942篇 |
1984年 | 608篇 |
1983年 | 489篇 |
1982年 | 258篇 |
1981年 | 191篇 |
1980年 | 145篇 |
1979年 | 292篇 |
1978年 | 83篇 |
1974年 | 82篇 |
1973年 | 103篇 |
1972年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
肝性脑病是终末期肝硬化的重要并发症,导致病人出现一系列神经及认知功能改变。肝移植术后病人在肝功能恢复的同时其认知功能也可明显改善。MRI可以从脑代谢、结构及功能方面更进一步揭示肝硬化病人移植术后认知及脑改变情况。综述肝移植术后认知改变的研究现状以及最新的多模态MRI技术在术后脑改变中的应用,及其在揭示术后认知恢复及残存损害的神经机制中的价值。 相似文献
33.
34.
35.
36.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
37.
S. Xing X. Zhang J. H. Liu X. Huang P. Zhou 《Clinical and experimental immunology》2019,195(1):121-131
Recent experimental strategies to reduce graft-versus-host disease (GVHD) have focused largely on modifying innate immunity. Toll-like receptor (TLR)-driven myeloid differentiation primary response 88 (MyD88)-dependent signalling pathways that initiate adaptive immune function are also critical for the pathogenesis of GVHD. This study aimed to delineate the role of host MyD88 in the development of acute GVHD following fully major histocompatibility complex-mismatched allogeneic bone marrow transplantation (BMT). When myeloablated BALB/c MyD88 knock-out recipients were transplanted with C57BL/6 (B6) donor cells, they developed significantly more severe GVHD than wild-type (WT) BALB/c hosts. The increased morbidity and mortality in MyD88–/– mice correlated with increased serum levels of lipopolysaccharide and elevated inflammatory cytokines in GVHD target organs. Additionally, MyD88 deficiency in BMT recipients led to increased donor T cell expansion and more donor CD11c+ cell intestinal infiltration with apoptotic cells but reduced proliferation of intestinal epithelial cells compared with that in WT BMT recipients. Decreased expression of tight junction mRNA in epithelial cells of MyD88–/– mice suggested that MyD88 contributes to intestinal integrity. Cox-2 expression in the GVHD-targeted organs of WT mice is increased upon GVHD induction, but this enhanced expression was obviously inhibited by MyD88 deficiency. The present findings demonstrate an unexpected role for host MyD88 in preventing GVHD after allogeneic BMT. 相似文献
38.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献
39.
40.